Press release
Investgiation announced for Long-Term Investors in Eyenovia, Inc. (NASDAQ: EYEN) who lost money
An investigation on behalf of investors in Eyenovia, Inc. (NASDAQ: EYEN) shares over potential wrongdoing at Eyenovia, Inc. was an
Investors who purchased shares of Eyenovia, Inc. (NASDAQ: EYEN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Eyenovia, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
New York based Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. Eyenovia, Inc. went public in January 2018.
Since then shares of Eyenovia, Inc. (NASDAQ: EYEN) declined from $10.74 per share on January 25, 2018 to as low as $3.99 per share on May 09, 2023.
Those who purchased shares of Eyenovia, Inc. (NASDAQ: EYEN) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investgiation announced for Long-Term Investors in Eyenovia, Inc. (NASDAQ: EYEN) who lost money here
News-ID: 3235467 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Eyenovia
Presbyopia Treatment Market Future Business Opportunities 2025-2032 | AbbVie, Ey …
The presbyopia treatment market is estimated to be valued at USD 20.17 Bn in 2025 and is expected to reach USD 29.54 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.
According to the latest research from CoherentMI, the Presbyopia Treatment Market is projected to experience significant growth between 2025 and 2032. This market intelligence report offers in-depth analysis based on thorough…
Presbyopia Treatment Market Future Business Opportunities 2025-2032 | AbbVie,Eye …
The presbyopia treatment market is estimated to be valued at USD 19.1 Bn in 2024 and is expected to reach USD 26.4 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
The release of the report "Presbyopia Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2032". This includes examining past deployments, current market conditions, and expected future deployments.…
Mydriasis Market Predicted to See Upsurge Through 2034, Highlights DelveInsight …
The Key Mydriasis Companies in the market include - Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd., and others.
DelveInsight's "Mydriasis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology as well as the Mydriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis…
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, a …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Mydriasis pipeline constitutes 3+ key companies continuously working towards developing 3+ Mydriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Mydriasis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/mydriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mydriasis Market.
The Mydriasis Pipeline report embraces in-depth commercial and clinical…
Mydriasis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by Delv …
DelveInsight's "Mydriasis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Mydriasis, historical and forecasted epidemiology as well as the Mydriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Mydriasis, offering comprehensive insights into the Mydriasis revenue trends, prevalence, and treatment landscape. The report delves into key Mydriasis…
Myopia Pipeline 2024 | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloud …
DelveInsight's, "Myopia Pipeline Insight 2024" report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Myopia pipeline landscape. It covers the Myopia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myopia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Myopia Pipeline.…
